



AMERICAN COLLEGE OF SURGEONS
*Inspiring Quality:
Highest Standards, Better Outcomes*

100+years

CQIP

Cancer Quality Improvement Program



Commission
on Cancer®

CQIP

Cancer Quality Improvement Program

St. Rita's Medical Center

6411560

Lima, OH



Annual Report 2015

Updated February 2016

Table of Contents

[Slide #5: Cancer Program Administrative Reports](#)

[Slide #11: Quality Measure Reports](#)

[Slide #40: Surgical Volume and Unadjusted 30, 90 Day Mortality After Complex Operations](#)

[Slide #50: Survival Reports](#)

[Slide #65: Breast Cancer - Additional Reports](#)

[Slide #75: Colon Cancer - Additional Reports](#)

[Slide #83: Non-Small-Cell Lung Cancer \(NSCLC\) - Additional Reports](#)

[Slide #92: Prostate Cancer - Additional Reports](#)

[Slide #102: Melanoma of the Skin Cancer - Additional Reports](#)

[Slide #110: Commission on Cancer](#)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Cancer Quality Improvement Program (CQIP)

- A data-driven, process and outcomes-based cancer quality improvement initiative
- Confidentially reports to 1,500 individual CoC-accredited hospitals their data as entered in NCDB (including comparisons with national data from all CoC-accredited programs)
- PDF download provides information to support the reports, technical details, report creation, and scientific justification and references for quality measures
- 2015 release provides CoC-accredited facilities with data on:
 - Compliance with CoC-adopted quality measures
 - Volume data for complex surgical oncology operations with 30-day and 90 day mortality
 - Unadjusted and risk-adjusted survival data for selected cancer sites
 - Other clinical data and administrative data, which will be updated and expanded annually



CoC Recommendations on the use of the CQIP Report

- The CQIP report should be presented and discussed at the Cancer Committee meeting
 - Major findings relevant to the cancer program should be listed
 - Interventions for improvement of quality of cancer care should be recommended
- Cancer Committee Leadership should present the report, major findings and recommendations to hospital leadership, including, but not limited to, CEO, COO, CMO, CNO, and bodies such as the Medical Staff Executive Committee, the hospital Quality Committee, etc
- As part of the accreditation process, these processes will be reviewed.



Cancer Program Administration Reports

Cancer Program Volume

- Total Case Volume Over Time, 2009–2013 *
- Insurance Status (including national comparison)


Cancer Program In/Out Migration

- Total In/Out Migration, 2009-2013 - My Facility
- In/Out Migration by Insurance Status, 2013 - My Facility

* Some facilities may see “Cranial Nerves Other” as one of their top ten cancer sites for case volume in the 2015 report that did not appear in prior CQIP reports. Prior to 2015 submissions, some “Other Cranial” histologies and primary sites such as meninges were incorrectly suppressed, but were allowed in 2015. The histologies and primary sites that were added may be found in the CQIP documentation.



Cancer Program Total Case Volume, 2009 - 2013 My Facility



If Miscellaneous appears in your graph, note that this is a SEER-defined group. The exact primary sites and histologies included in this group may be found in the CQIP documentation



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Cancer Program Total Case Volume, 2009 - 2013 My Facility

| | 2009 | 2010 | 2011 | 2012 | 2013 |
|--|------|------|------|------|------|
| Breast | 158 | 141 | 141 | 170 | 170 |
| Lung, Bronchus - Non-Small Cell Carcinoma | 91 | 94 | 82 | 96 | 82 |
| Prostate | 68 | 71 | 83 | 74 | 64 |
| Urinary Bladder | 29 | 21 | 40 | 49 | 49 |
| Miscellaneous | 20 | 24 | 22 | 22 | 46 |
| Colon | 64 | 49 | 69 | 65 | 44 |
| Lung, Bronchus - Small Cell Carcinoma | 22 | 21 | 20 | 31 | 28 |
| Kidney and Renal Pelvis | 27 | 18 | 35 | 33 | 26 |
| NHL - Nodal | 23 | 15 | 23 | 24 | 26 |
| Thyroid | 16 | 31 | 25 | 24 | 25 |
| All Other Sites | 227 | 189 | 198 | 242 | 214 |
| TOTAL | 745 | 674 | 738 | 830 | 774 |

If Miscellaneous appears in your table, note that this is a SEER-defined group. The exact primary sites and histologies included in this group may be found in the CQIP documentation



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Insurance Status, 2010 - 2013 - My Facility vs. All CoC



| | 2010 My Facility | 2011 My Facility | 2012 My Facility | 2013 My Facility | 2013 All CoC |
|---------------------------------|------------------|------------------|------------------|------------------|-------------------|
| Not Insured | 5.3 % (n=36) | 4.7 % (n=35) | 6.1 % (n=51) | 5.9 % (n=46) | 3.5 % (n=43968) |
| Private/ Managed | 37.2 % (n=251) | 33.6 % (n=248) | 33.5 % (n=278) | 34.6 % (n=268) | 38.9 % (n=483067) |
| Medicaid | 4.3 % (n=29) | 3.4 % (n=25) | 4.5 % (n=37) | 5.7 % (n=44) | 6.3 % (n=78081) |
| Medicare | 51.5 % (n=347) | 56.8 % (n=419) | 54 % (n=448) | 53.7 % (n=416) | 46.4 % (n=576523) |
| Other Government | 0.7 % (n=5) | 0.1 % (n=1) | 0.2 % (n=2) | 0 % (n=0) | 2.8 % (n=35372) |
| Insurance Status Unknown | 0.9 % (n=6) | 1.4 % (n=10) | 1.7 % (n=14) | 0 % (n=0) | 2.1 % (n=26364) |



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Total In/Out Migration, 2009 - 2013 - My Facility



| | 2009 | 2010 | 2011 | 2012 | 2013 |
|---|----------------|----------------|----------------|----------------|----------------|
| Diagnosed Here and Treated Elsewhere | 5.9 % (n=44) | 7.6 % (n=51) | 9.6 % (n=71) | 12.3 % (n=102) | 14 % (n=108) |
| Diagnosed and Treated Here | 75 % (n=559) | 71.2 % (n=480) | 70.9 % (n=523) | 61.3 % (n=509) | 59.4 % (n=460) |
| Diagnosed Elsewhere and Treated Here | 19.1 % (n=142) | 21.2 % (n=143) | 19.5 % (n=144) | 26.4 % (n=219) | 26.6 % (n=206) |



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

In/Out Migration by Insurance Status, 2013 - My Facility



| | Not Insured | Private/Managed | Medicaid | Medicare | Other Government | Unknown |
|---|--------------|-----------------|--------------|----------------|------------------|-----------|
| Diagnosed Here and Treated Elsewhere | 0.6 % (n=5) | 4.3 % (n=33) | 0.8 % (n=6) | 8.3 % (n=64) | 0 % (n=0) | 0 % (n=0) |
| Diagnosed and Treated Here | 3.6 % (n=28) | 20.5 % (n=159) | 3.6 % (n=28) | 31.7 % (n=245) | 0 % (n=0) | 0 % (n=0) |
| Diagnosed Elsewhere and Treated Here | 1.7 % (n=13) | 9.8 % (n=76) | 1.3 % (n=10) | 13.8 % (n=107) | 0 % (n=0) | 0 % (n=0) |



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measure Reports

Accountability Measure

- Considered the current standard of care based on clinical trial evidence Commission on Cancer Standard 4.4.

Quality Improvement Measure (QI)

- Demonstrates good practice based on consensus. Usually not based on clinical trial evidence. Commission on Cancer Standard 4.5 addresses compliance with quality improvement.

Surveillance Measure

- Used at the community, regional, and/or national level to monitor patterns and trends of care in order to guide policymaking and resource allocation.



Cancer Program Practice Profile (CP³R) Estimated Performance Rates

- Breast (6)
- Colon (2)
- Gastric (1)
- Ovary (1)
- Cervix (3)
- Endometrium (2)
- Non-Small Cell Lung (3)
- Rectum (1)

Extensive assessment and validation of the measures were performed using cancer registry data reported to the National Cancer Data Base (NCDB).

Disclaimer: All measures are designed to assess performance at the hospital or systems-level, and are not intended for application to individual physician performance.



Quality Measure Reports – Breast

- **BCSRT:** Breast radiation after breast conserving surgery (NQF 0219 – Accountability)
- **MAC:** Combination chemotherapy for hormone receptor negative breast cancer (NQF 0559 – Accountability)
- **HT:** Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 – Accountability)
- **BCS:** Breast conserving surgery rate (Surveillance)
- **MASRT:** Radiation therapy recommended or administered following mastectomy within 1 year of diagnosis for women with 4 or more positive regional lymph nodes (Accountability)
- **nBx:** Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement)

NQF = National Quality Forum Endorsed Measure



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

BREAST, 2013, BCSRT: Breast radiation after breast conserving surgery (NQF 0219 - Accountability)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|-------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 89.6 % | 93.9 % | 93 % | 94.7 % | 91.8 % | 91.5 % |
| Denominator | 48 | 2524 | 9505 | 5366 | 23751 | 52944 |
| 95 % CI | (81.0,98.2) | (93.0,94.8) | (92.5,93.5) | (94.1,95.3) | (91.5,92.1) | (91.3,91.7) |

Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

BREAST, 2013, MAC: Combination chemotherapy for hormone receptor negative breast cancer (NQF 0559 - Accountability)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|---------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 100 % | 91.5 % | 92.6 % | 93 % | 93.3 % | 92.3 % |
| Denominator | 6 | 568 | 2204 | 1147 | 5304 | 12397 |
| 95 % CI | (100.0,100.0) | (89.2,93.8) | (91.5,93.7) | (91.5,94.5) | (92.6,94.0) | (91.8,92.8) |

Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

BREAST, 2013, HT: Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 - Accountability)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|-------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 85.3 % | 93.8 % | 93 % | 94.7 % | 91.1 % | 91.2 % |
| Denominator | 34 | 3503 | 12879 | 7170 | 33733 | 74509 |
| 95 % CI | (73.4,97.2) | (93.0,94.6) | (92.6,93.4) | (94.2,95.2) | (90.8,91.4) | (91.0,91.4) |

Tamoxifen or third generation Aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor positive breast cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

BREAST, 2013, BCS: Breast conserving surgery rate (Surveillance)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|-------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 69.5 % | 64.9 % | 65.2 % | 66.4 % | 62.9 % | 62.6 % |
| Denominator | 82 | 5327 | 20749 | 11727 | 55796 | 120267 |
| 95 % CI | (59.5,79.5) | (63.6,66.2) | (64.6,65.8) | (65.5,67.3) | (62.5,63.3) | (62.3,62.9) |

Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

BREAST, 2013, MASRT: Post-mastectomy radiation for women with 4 or more positive regional lymph nodes (Accountability)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|--------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 75 % | 87.8 % | 90.4 % | 89.6 % | 87.3 % | 87.6 % |
| Denominator | 4 | 329 | 1294 | 689 | 3231 | 7473 |
| 95 % CI | (32.6,100.0) | (84.3,91.3) | (88.8,92.0) | (87.3,91.9) | (86.2,88.4) | (86.9,88.3) |

Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

BREAST, 2013, nBx: Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|-------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 86.7 % | 86.7 % | 90.7 % | 89.4 % | 90.2 % | 90.3 % |
| Denominator | 105 | 6431 | 24633 | 13934 | 60789 | 126851 |
| 95 % CI | (80.2,93.2) | (85.9,87.5) | (90.3,91.1) | (88.9,89.9) | (90.0,90.4) | (90.1,90.5) |

Image or palpation-guided needle biopsy (core or FNA) is performed to establish diagnosis of breast cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measure Reports - Cervix


CBRRT: Use of brachytherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer (Surveillance)

CERRT: Radiation therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer (Surveillance)

CERCT: Chemotherapy administered to cervical cancer patients who received radiation for stages IB2-IV cancer (Group 1) or with positive pelvic nodes, positive surgical margin, and/or positive parametrium (Group 2) (Surveillance)



CERVIX, 2013, CBRRT: Brachytherapy in cervical cancer patients treated with primary radiation (Surveillance)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|---------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 100 % | 76.2 % | 75.1 % | 80.3 % | 67.1 % | 72.5 % |
| Denominator | 2 | 122 | 458 | 305 | 952 | 2855 |
| 95 % CI | (100.0,100.0) | (68.6,83.8) | (71.1,79.1) | (75.8,84.8) | (64.1,70.1) | (70.9,74.1) |

Use of brachytherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

CERVIX, 2013, CERRT: Radiation therapy completed within 60 days among women diagnosed with cervical cancer (Surveillance)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|---------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 100 % | 81.4 % | 80 % | 79.2 % | 79.8 % | 79.7 % |
| Denominator | 1 | 118 | 430 | 284 | 917 | 2701 |
| 95 % CI | (100.0,100.0) | (74.4,88.4) | (76.2,83.8) | (74.5,83.9) | (77.2,82.4) | (78.2,81.2) |

Radiation therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

CERVIX, 2013, CERCT: Chemotherapy for cervical cancer patients who received radiation (Surveillance)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|---------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 100 % | 92.2 % | 90.6 % | 87.2 % | 86.6 % | 88.2 % |
| Denominator | 2 | 154 | 596 | 366 | 1296 | 3770 |
| 95 % CI | (100.0,100.0) | (88.0,96.4) | (88.3,92.9) | (83.8,90.6) | (84.7,88.5) | (87.2,89.2) |

Chemotherapy administered to cervical cancer patients who received radiation for stages IB2-IV cancer (Group 1) or with positive pelvic nodes, positive surgical margin, and/or positive parametrium (Group 2) (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measure Reports - Colon

- **ACT:** Adjuvant chemotherapy for lymph node positive colon cancer (NQF 0223 – Accountability)
- **12RLN:** At least 12 lymph nodes are removed and examined as part of primary colon cancer resection (NQF 0225 – Quality Improvement)

NQF = National Quality Forum Endorsed Measure



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

COLON, 2013, ACT: Adjuvant chemotherapy for lymph node positive colon cancer (NQF 0223 - Accountability)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|--------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 87.5 % | 91 % | 91.8 % | 91.7 % | 89.5 % | 89.3 % |
| Denominator | 8 | 489 | 1710 | 965 | 4328 | 9718 |
| 95 % CI | (64.6,100.0) | (88.5,93.5) | (90.5,93.1) | (90.0,93.4) | (88.6,90.4) | (88.7,89.9) |

Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

COLON, 2013, 12RL: At least 12 regional lymph nodes removed and pathologically examined for resected colon cancer (NQF 0225 - Quality Improvement)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|--------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 94.4 % | 88.4 % | 90.6 % | 88.2 % | 89.7 % | 89.9 % |
| Denominator | 18 | 2074 | 7455 | 4296 | 19142 | 40959 |
| 95 % CI | (83.8,100.0) | (87.0,89.8) | (89.9,91.3) | (87.2,89.2) | (89.3,90.1) | (89.6,90.2) |

At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program




© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measure Reports - Endometrium

- **ENDCTRT:** Chemotherapy and/or radiation administered to patients with Stage IIIC or IV Endometrial cancer (Surveillance)
- **ENDRLC:** Endoscopic, laparoscopic, or robotic surgery performed for all Endometrial cancer (Surveillance)



ENDOMETRIUM, 2013, ENDCTRT: Chemotherapy and/or radiation administered to patients with Endometrial cancer (Surveillance)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | NA | 81.1 % | 82.6 % | 83.8 % | 76.6 % | 79.8 % |
| Denominator | 0 | 90 | 384 | 240 | 843 | 2394 |
| 95 % CI | (0.0,0.0) | (73.0,89.2) | (78.8,86.4) | (79.1,88.5) | (73.7,79.5) | (78.2,81.4) |

Chemotherapy and/or radiation recommended to patients with Stage IIIC or IV Endometrial cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

ENDOMETRIUM, 2013, ENDLRC: Endoscopic, laparoscopic, or robotic surgery performed for all Endometrial cancer (Surveillance)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|---------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 100 % | 58.7 % | 68.3 % | 65.4 % | 75.8 % | 72.3 % |
| Denominator | 1 | 1089 | 4580 | 2748 | 10250 | 26531 |
| 95 % CI | (100.0,100.0) | (55.8,61.6) | (67.0,69.6) | (63.6,67.2) | (75.0,76.6) | (71.8,72.8) |

Endoscopic, laparoscopic, or robotic surgery performed for all Endometrial cancer (excluding sarcoma and lymphoma), for all stages except stage IV. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+years

CQIP

Cancer Quality Improvement Program




© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measure Reports - Gastric

- **G15RLN:** At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement)



GASTRIC, 2013, G15RLN: At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|-------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 50 % | 54.1 % | 53.2 % | 50.5 % | 46.2 % | 54.3 % |
| Denominator | 2 | 111 | 432 | 220 | 991 | 2846 |
| 95 % CI | (0.0,100.0) | (44.8,63.4) | (48.5,57.9) | (43.9,57.1) | (43.1,49.3) | (52.5,56.1) |

At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program




© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measure Reports - Non-Small Cell Lung

- **10RLN:** At least 10 regional lymph nodes removed and pathologically examined for AJCC stage IA, IB, IIA, and IIB resected NSCLC (Surveillance)
- **LCT:** Systemic chemotherapy is administered or recommended within 4 months prior to surgery or within 6 months postoperatively for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC (Quality Improvement)
- **LNoSurg:** Surgery is not the first course of treatment for cN2, M0 cases (Quality Improvement)



NSCLC, 2013, 10RLN: At least 10 regional lymph nodes removed and pathologically examined for resected NSCLC (Surveillance)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 20 % | 37.7 % | 39.3 % | 47.5 % | 34.5 % | 41 % |
| Denominator | 10 | 1012 | 3552 | 2215 | 8121 | 20055 |
| 95 % CI | (0.0,44.8) | (34.7,40.7) | (37.7,40.9) | (45.4,49.6) | (33.5,35.5) | (40.3,41.7) |

At least 10 regional lymph nodes are removed and pathologically examined for AJCC stage IA, IB, IIA, and IIB resected NSCLC. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

NSCLC, 2013, LCT: Systemic chemotherapy administered or recommended for pre or postoperatively resected NSCLC (Quality Improvement)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|---------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 100 % | 91 % | 92.8 % | 93.6 % | 89.4 % | 89.6 % |
| Denominator | 1 | 188 | 766 | 451 | 1669 | 4231 |
| 95 % CI | (100.0,100.0) | (86.9,95.1) | (91.0,94.6) | (91.3,95.9) | (87.9,90.9) | (88.7,90.5) |

Systemic chemotherapy administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is considered for surgically resected cases with pathologic, lymph node-positive (pN1) or (pN2) NSCLC. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

NSCLC, 2013, LNoSurg: Surgery is not the first course of treatment for NSCLC (Quality Improvement)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|---------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 100 % | 90.7 % | 91.8 % | 91.1 % | 91.9 % | 92 % |
| Denominator | 6 | 591 | 1947 | 1081 | 4135 | 9692 |
| 95 % CI | (100.0,100.0) | (88.4,93.0) | (90.6,93.0) | (89.4,92.8) | (91.1,92.7) | (91.5,92.5) |

Surgery is not the first course of treatment for cN2, M0 cases. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+years

CQIP

Cancer Quality Improvement Program




© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measure Reports - Ovary

- **OVSAL:** Salpingo-oophorectomy with omentectomy, debulking; cytoreductive surgery, or pelvic exenteration in Stages I-IIIC Ovarian cancer (Surveillance)



OVARY, 2013, OVSAL: Salpingo-oophorectomy with omentectomy, debulking; cytoreductive surgery, or pelvic exenteration for Ovarian cancers (Surveillance)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | NA | 70.4 % | 69.6 % | 69.5 % | 69.5 % | 70.5 % |
| Denominator | 0 | 351 | 1410 | 802 | 3129 | 8240 |
| 95 % CI | (0.0,0.0) | (65.6,75.2) | (67.2,72.0) | (66.3,72.7) | (67.9,71.1) | (69.5,71.5) |

Salpingo-oophorectomy with omentectomy, debulking; cytoreductive surgery, or pelvic exenteration in Stages I-IIIc Ovarian cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+years

CQIP

Cancer Quality Improvement Program




© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measure Reports - Rectum

- **RECRT:** Radiation therapy is administered as a component of therapy along with surgical resection (Surveillance)
- **RECRTCT:** Chemo and radiation therapy is administered or recommended for resected rectal cancers (Quality Improvement)



RECTUM, 2013, RECRTCT: Chemo and Radiation therapy is administered or recommended for resected rectal cancers (Quality Improvement)



| | My Program | My State (OH) | My Census Region (East North Central) | My ACS Division (East Central) | My CoC Program Type (CCCP) | All CoC Programs |
|-------------------------|---------------|---------------|---------------------------------------|--------------------------------|----------------------------|------------------|
| Performance Rate | 100 % | 86.7 % | 87 % | 89.4 % | 86.3 % | 86.3 % |
| Denominator | 7 | 248 | 1067 | 566 | 2359 | 5807 |
| 95 % CI | (100.0,100.0) | (82.5,90.9) | (85.0,89.0) | (86.9,91.9) | (84.9,87.7) | (85.4,87.2) |

Preop CT & RT for clin AJCC T3N0, T4N0, or Stage III; or Postop CT & RT within 180 days of diagnosis for clin AJCC T1-2N0 with path AJCC T3N0, T4N0, or Stage III; or recommended; for patients < age 80 resected rectal cancer. (CP3R data as of 11/02/2015)



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Volume and Unadjusted 30, 90 Day Mortality After Selected Complex Cancer Operations

- Cystectomy
- Esophagectomy
- Gastrectomy
- Pancreatectomy
- Rectal resection
- Non–Small-Cell Lung Cancer (NSCLC) resection



Methods, 30, 90 Day Mortality

- Resections include FORDs surgery codes 30-80, and Surgery at this Facility only
- Rates are NOT adjusted for any risk factors such as age or stage
- Rates are compared to 30, 90 day mortality for all CoC facilities, and for facilities with at least 30 resections in 2011-2013 diagnosis years (High volume facilities)
- 95% Confidence Intervals are presented for your facility and for all CoC and for high volume facilities. If your facility's confidence intervals overlap with the all CoC or high volume facilities than your mortality rate is not significantly different from the aggregate rates.




Methods, 30, 90 Day Mortality

- For 30 day mortality, patients who were alive at last contact had to have at least 30 days of follow up from the surgery date to be included in the denominator. Similarly for 90 day mortality, patients who were alive at last contact had to have a least 90 days of follow up from the surgery date. If the denominator for 90 day mortality includes fewer patients than the denominator for 30 day mortality, it means that some patients last known to be alive did not have 90 days of follow up from the surgery date.
- These rates are intended for internal institutional use only, with the goal of better understanding your program's performance while identifying opportunities for improved cancer care.



Number of Major Surgical Resections for Selected Cancers, 2011 - 2013 - My Facility



| | Cystectomy | Esophagectomy | Gastrectomy | Rectal Resection | Pancreatectomy | Lung Resection |
|---------------------|------------|---------------|-------------|------------------|----------------|----------------|
| 2011 Diagnosis Year | 3 | 0 | 2 | 6 | 0 | 27 |
| 2012 Diagnosis Year | 2 | 0 | 1 | 8 | 0 | 20 |
| 2013 Diagnosis Year | 3 | 0 | 2 | 9 | 0 | 18 |

* includes surgery codes 30-80 only



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Cystectomies, Unadjusted 30, 90 Day Mortality, 95% CI, 2011 - 2013 My Facility vs. All CoC and CoC High Volume



| | My Facility | | All CoC | | CoC High Volume | |
|--------------------------|-------------|------------|-----------|-----------|-----------------|-----------|
| | 30 Day | 90 Day | 30 Day | 90 Day | 30 Day | 90 Day |
| Mortality Percent | 0.0% | 0.0% | 2.4% | 7.0% | 2.0% | 6.2% |
| 95 % CI | (0.0,37.4) | (0.0,49.9) | (2.2,2.6) | (6.6,7.3) | (1.8,2.2) | (5.8,6.6) |
| Deaths | 0 | 0 | 419 | 1,142 | 199 | 576 |
| Resections | 8 | 6 | 17,362 | 16,392 | 9,973 | 9,314 |

*NA No resections, or < 30 or < 90 days of follow up for alive patients



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Esophagectomies, Unadjusted 30, 90 Day Mortality, 95% CI, 2011 - 2013 My Facility vs. All CoC and CoC High Volume



| | My Facility | | All CoC | | CoC High Volume | |
|--------------------------|-------------|--------|-----------|-----------|-----------------|-----------|
| | 30 Day | 90 Day | 30 Day | 90 Day | 30 Day | 90 Day |
| Mortality Percent | *NA | *NA | 3.6% | 8.8% | 2.5% | 6.8% |
| 95 % CI | *NA | *NA | (3.3,4.0) | (8.3,9.4) | (2.1,3.0) | (6.1,7.6) |
| Deaths | *NA | *NA | 284 | 642 | 94 | 233 |
| Resections | *NA | *NA | 7,806 | 7,264 | 3,761 | 3,426 |

*NA No resections, or < 30 or < 90 days of follow up for alive patients



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Gastrectomies, Unadjusted 30, 90 Day Mortality, 95% CI, 2011 - 2013 My Facility vs. All CoC and CoC High Volume



| | My Facility | | All CoC | | CoC High Volume | |
|--------------------------|-------------|-------------|-----------|-----------|-----------------|-----------|
| | 30 Day | 90 Day | 30 Day | 90 Day | 30 Day | 90 Day |
| Mortality Percent | 25.0% | 25.0% | 3.7% | 7.5% | 2.6% | 5.7% |
| 95 % CI | (1.3,100.0) | (1.3,100.0) | (3.4,3.9) | (7.2,7.9) | (2.3,2.8) | (5.3,6.2) |
| Deaths | 1 | 1 | 712 | 1,385 | 266 | 553 |
| Resections | 4 | 4 | 19,412 | 18,377 | 10,350 | 9,642 |

*NA No resections, or < 30 or < 90 days of follow up for alive patients



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

NSCLC Resections, Unadjusted 30, 90 Day Mortality, 95% CI, 2011-2013 My Facility vs. All CoC and CoC High Volume



| | My Facility | | All CoC | | CoC High Volume | |
|--------------------------|-------------|------------|-----------|-----------|-----------------|-----------|
| | 30 Day | 90 Day | 30 Day | 90 Day | 30 Day | 90 Day |
| Mortality Percent | 7.7% | 10.9% | 2.5% | 4.8% | 2.4% | 4.7% |
| 95 % CI | (3.0,16.2) | (5.1,20.5) | (2.4,2.6) | (4.6,4.9) | (2.3,2.5) | (4.5,4.8) |
| Deaths | 5 | 7 | 1,883 | 3,513 | 1,689 | 3,151 |
| Resections | 65 | 64 | 76,583 | 73,683 | 69,953 | 67,246 |

*NA No resections, or < 30 or < 90 days of follow up for alive patients



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Pancreatectomies, Unadjusted 30, 90 Day Mortality, 95% CI, 2011 - 2013 My Facility vs. All CoC and CoC High Volume



| | My Facility | | All CoC | | CoC High Volume | |
|--------------------------|-------------|--------|-----------|-----------|-----------------|-----------|
| | 30 Day | 90 Day | 30 Day | 90 Day | 30 Day | 90 Day |
| Mortality Percent | *NA | *NA | 2.8% | 6.1% | 2.2% | 5.0% |
| 95 % CI | *NA | *NA | (2.6,3.0) | (5.8,6.4) | (2.0,2.4) | (4.7,5.3) |
| Deaths | *NA | *NA | 581 | 1,201 | 331 | 724 |
| Resections | *NA | *NA | 20,542 | 19,654 | 15,319 | 14,587 |

*NA No resections, or < 30 or < 90 days of follow up for alive patients



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Rectal Resections, Unadjusted 30, 90 Day Mortality, 95% CI, 2011 - 2013 My Facility vs. All CoC and CoC High Volume



| | My Facility | | All CoC | | CoC High Volume | |
|--------------------------|-------------|------------|-----------|-----------|-----------------|-----------|
| | 30 Day | 90 Day | 30 Day | 90 Day | 30 Day | 90 Day |
| Mortality Percent | 0.0% | 4.8% | 1.5% | 3.0% | 1.2% | 2.6% |
| 95 % CI | (0.0,13.0) | (0.2,22.6) | (1.4,1.7) | (2.9,3.2) | (1.1,1.4) | (2.4,2.8) |
| Deaths | 0 | 1 | 505 | 943 | 268 | 537 |
| Resections | 23 | 21 | 32,843 | 30,935 | 21,909 | 20,538 |

*NA No resections, or < 30 or < 90 days of follow up for alive patients



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.